These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

515 related articles for article (PubMed ID: 19001161)

  • 1. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
    Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
    Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
    Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
    J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of the central memory and Tr1-like regulatory T cells in multiple sclerosis patients responsive to interferon-beta therapy.
    Chiarini M; Serana F; Zanotti C; Capra R; Rasia S; Rottoli M; Rovaris M; Caputo D; Cavaletti G; Frigo M; Frigeni B; Clerici R; Rezzonico M; Caimi L; Imberti L
    Mult Scler; 2012 Jun; 18(6):788-98. PubMed ID: 22086901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon beta-1a therapy enhances CD4+ regulatory T-cell function: an ex vivo and in vitro longitudinal study in relapsing-remitting multiple sclerosis.
    de Andrés C; Aristimuño C; de Las Heras V; Martínez-Ginés ML; Bartolomé M; Arroyo R; Navarro J; Giménez-Roldán S; Fernández-Cruz E; Sánchez-Ramón S
    J Neuroimmunol; 2007 Jan; 182(1-2):204-11. PubMed ID: 17157927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IFNbeta-1a therapy for multiple sclerosis expands regulatory CD8+ T cells and decreases memory CD8+ subset: a longitudinal 1-year study.
    Aristimuño C; de Andrés C; Bartolomé M; de las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
    Clin Immunol; 2010 Feb; 134(2):148-57. PubMed ID: 19900844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fine-tuning the homeostasis of regulatory T cells: new mechanism of immunomodulatory therapy in multiple sclerosis.
    Hofstetter HH; Stüve O; Hartung HP
    Arch Neurol; 2008 Nov; 65(11):1417-8. PubMed ID: 19001158
    [No Abstract]   [Full Text] [Related]  

  • 7. Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate.
    Chiarini M; Sottini A; Ghidini C; Zanotti C; Serana F; Rottoli M; Zaffaroni M; Bergamaschi R; Cordioli C; Capra R; Imberti L
    Mult Scler; 2010 Feb; 16(2):218-27. PubMed ID: 20007428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy.
    Saresella M; Marventano I; Longhi R; Lissoni F; Trabattoni D; Mendozzi L; Caputo D; Clerici M
    FASEB J; 2008 Oct; 22(10):3500-8. PubMed ID: 18587005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical response to interferon-beta-1a may be linked to low baseline circulating BDCA1 myeloid dendritic cells Differential role of circulating dendritic cells and CD4+ regulatory T-cells in relapsing-remitting multiple sclerosis: a 1-year longitudinal study.
    de Andrés C; Aristimuño C; Bartolomé M; de Las Heras V; Martínez-Ginés ML; Arroyo R; Fernández-Cruz E; Sánchez-Ramón S
    J Neuroimmunol; 2009 Jul; 212(1-2):112-20. PubMed ID: 19446889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glatiramer acetate improves regulatory T-cell function by expansion of naive CD4(+)CD25(+)FOXP3(+)CD31(+) T-cells in patients with multiple sclerosis.
    Haas J; Korporal M; Balint B; Fritzsching B; Schwarz A; Wildemann B
    J Neuroimmunol; 2009 Nov; 216(1-2):113-7. PubMed ID: 19646767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memory and naïve B-cell subsets in patients with multiple sclerosis.
    Niino M; Hirotani M; Miyazaki Y; Sasaki H
    Neurosci Lett; 2009 Oct; 464(1):74-8. PubMed ID: 19666086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymic output and peripheral T lymphocyte subsets in relapsing--remitting multiple sclerosis patients treated or not by IFN-beta.
    Puissant-Lubrano B; Viala F; Winterton P; Abbal M; Clanet M; Blancher A
    J Neuroimmunol; 2008 Jan; 193(1-2):188-94. PubMed ID: 18068811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar sensitivity of regulatory T cells towards CD95L-mediated apoptosis in patients with multiple sclerosis and healthy individuals.
    Fritzsching B; Korporal M; Haas J; Krammer PH; Suri-Payer E; Wildemann B
    J Neurol Sci; 2006 Dec; 251(1-2):91-7. PubMed ID: 17092518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
    Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
    Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon-β therapy.
    Cosentino M; Zaffaroni M; Trojano M; Giorelli M; Pica C; Rasini E; Bombelli R; Ferrari M; Ghezzi A; Comi G; Livrea P; Lecchini S; Marino F
    Neuroimmunomodulation; 2012; 19(5):283-92. PubMed ID: 22472872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations.
    Praksova P; Stourac P; Bednarik J; Vlckova E; Mikulkova Z; Michalek J
    J Neurol Sci; 2012 Aug; 319(1-2):18-23. PubMed ID: 22676847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
    Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulin-like transcript 3, an inhibitor of T cell activation, is reduced on blood monocytes during multiple sclerosis relapses and is induced by interferon beta-1b.
    Jensen MA; Yanowitch RN; Reder AT; White DM; Arnason BG
    Mult Scler; 2010 Jan; 16(1):30-8. PubMed ID: 20007427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation in multiple sclerosis.
    Schwab N; Zozulya AL; Kieseier BC; Toyka KV; Wiendl H
    J Immunol; 2010 May; 184(9):5368-74. PubMed ID: 20357264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.